Pfizer Inc. will study the effectiveness of its vaccine against COVID-19 by inoculating the entire population over the age of 12 in a town in southern Brazil, the company said on Wednesday, APA reports quoting Reuters.
The study will be conducted in Toledo, population 143,000, in the west of Parana state, together with Brazil's National Vaccination Program, local health authorities, a hospital and a federal university.
Pfizer, which developed the vaccine with German partner BioNTech SE , said the purpose was to study transmission of the coronavirus in a "real-life scenario" after the population has been vaccinated.
"The initiative is the first and only of its kind to be undertaken in collaboration with the pharmaceutical company in a developing country," Pfizer said.